Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma-Reference-Cited by-同舟云学术

Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma

Published:2014-07-16 Issue:3 Volume:20 Page:129-136
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zhou Xiaolei¹,Wang Jianmin¹,Zhang Jessica¹,Copley-Merriman Catherine¹,Torigoe Yasuhiro²,Reyes Carolina²,Seymour John F.³,Offner Fritz C.⁴,Trneny Marek⁵,Salles Gilles Andre⁶

Affiliation:

1. RTI Health SolutionsResearch Triangle Park, NC, USA

2. Genentech Inc., South San Francisco, CA, USA

3. Department of HaematologyPeter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia

4. Dienst HematologieUZ Gent, Gent, Belgium

5. 1st Dept MedicineCharles University General Hospital, Prague, Czech Republic

6. HématologieHospices Civils de Lyon—Université de Lyon, Pierre-Bénite, France

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1179/1607845414Y.0000000179

Reference26 articles.

1. Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century

2. Improved Survival of Follicular Lymphoma Patients in the United States

3. Rituximab maintenance therapy in indolent NHL: a clinical review

4. Rituximab maintenance in follicular lymphoma patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review;The Lancet Haematology;2020-12

2. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews;PharmacoEconomics - Open;2020-03-21

3. Where to start? Upfront therapy for follicular lymphoma in 2018;Hematology;2018-11-30

4. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma;JAMA Oncology;2018-06-01